Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(32)
•••
Comment by DukeDilligenceon Mar 22, 2018 2:40pm
88 Views
Post# 27763338

RE:RE:RE:RE:Insider sells 500,000 ....Ouch

RE:RE:RE:RE:Insider sells 500,000 ....Ouch
Edcando wrote:
DukeDilligence wrote:
Newbie111 wrote: u also said it would go down to .25 today lol


it will now...But...Just keep holding...lol
 


-Those that are holding aren't as concerned about today's price as they are with how high it will be later. 

- If you truly believe your own bs, then why are you here wasting your time? Even a broken clock is right twice a day , but its still a broken clock (ie even if price drops short term you're still going to be looking pretty stupid later, and have made less money than if you just rode the sp up)

I'm here to guide you....I'm here to help....The insider sold because he knows the same thing the rest of the experienced investors know....This will be a big stock...Not till the end of the year.....That's if phase 3 reults are good...The market will tire of holding this..The SP is going into the .20's long before phase 3 is complete...Rookies might hold 'Long and stong'...The rest of the market won't.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities